Longevity Medicine, Functional Wellness & Anti-Aging Insights from HormoneSynergy®

GLP-1 medications can produce substantial fat loss, and some lean mass commonly falls with it. That does not mean semaglutide or tirzepatide uniquely destroy muscle. Newer research finds that the proportion of lean mass lost with GLP-1 treatment is broadly comparable with substantial weight loss achieved through lifestyle intervention, while resistance training improves muscle preservation. At HormoneSynergy®, we typically do not see the dramatic muscle loss suggested by headlines when weight loss is managed with adequate protein, resistance and weight-bearing exercise, body-composition tracking, and appropriate dosing.

“Microdosing” semaglutide and tirzepatide has become one of the latest trends in weight loss and longevity medicine. The term sounds precise, but there is no standardized medical definition of a GLP-1 microdose. Some patients genuinely do well at lower doses, and using the minimum effective dose can be good medicine. That is different from taking tiny amounts casually, stretching medication for cost, or assuming less drug automatically means safer or healthier treatment. HormoneSynergy® focuses on response, body composition, metabolic health, nutrition, muscle preservation, and long-term maintenance rather than chasing a dosing trend.

Two inflammation indices calculated from a routine CBC—SII and SIRI—may reveal additional information about cardiovascular and mortality risk without another blood test. Interesting? Yes. Ready to become new longevity targets? Not yet.

A new analysis of the three-year PREVIEW diabetes-prevention trial raises a more useful question than whether the scale moved: did insulin resistance actually improve, and did the improvement last? The answer is more complicated than the viral headline suggests.

A heart surgeon argues that metabolic dysfunction matters more than cholesterol in coronary disease. He is right that metabolic health deserves far more attention. But turning that insight into a choice between metabolism and atherogenic lipoproteins creates another oversimplification.

BPC-157, CJC-1295, TB-500, MOTS-c and other unapproved peptides are increasingly marketed for healing, recovery, muscle, metabolism and longevity. Some have intriguing biology. That is very different from having convincing human evidence, established dosing and a known long-term safety profile.

A new longevity concierge program ranges from $75,000 to $1 million and includes physicians, advanced imaging, extensive biomarkers, wearables, supplements and medications. Much of the medicine is legitimate. The price tag raises a different question: when does comprehensive care become expensive excess?

Birth control pills and menopausal hormone therapy can both be used during perimenopause, but they are designed for different jobs. Combined hormonal contraceptives suppress ovulation and prevent pregnancy. Menopausal hormone therapy is designed to replace declining hormones and treat the physiologic effects of the menopause transition. For more than 25 years, Dr. Kathryn Retzler has questioned why oral contraceptives and antidepressants so often became default answers for women with perimenopausal symptoms without first asking whether changing estrogen, progesterone, and androgen physiology deserved direct attention.

Progesterone and synthetic progestins are often treated as interchangeable, but they are different molecules with different pharmacology. The Women's Health Initiative used medroxyprogesterone acetate, not micronized progesterone, and newer evidence suggests the choice of progestogen may matter for breast, vascular, metabolic, mood, and sleep effects. At HormoneSynergy®, Dr. Kathryn Retzler generally prefers micronized progesterone, using FDA-approved Prometrium® or compounded progesterone when appropriate, with continuous or cyclical dosing based on the woman and her treatment plan.

Estradiol patches and oral estradiol can both relieve menopausal symptoms, but they do not travel through the body the same way. Oral estrogen passes through the liver before reaching the circulation, while transdermal estradiol enters through the skin and largely avoids first-pass liver metabolism. That difference can affect clotting, triglycerides, binding proteins, dosing stability, and which route makes the most sense for an individual woman. At HormoneSynergy®, Dr. Kathryn Retzler generally favors non-oral estradiol when systemic estrogen is appropriate, while still making room for patient preference and other delivery options.

Microbiome stool tests can identify hundreds or thousands of organisms and provide detailed information about microbial diversity and function. The harder question is whether those findings change clinical care. HormoneSynergy® occasionally uses advanced stool testing when there is a defined reason for ordering it, but a microbiome report is not a diagnosis. Pathogens, inflammation, digestive markers, symptoms, diet, medications, and the clinical question still matter more than whether one bacterial species falls above or below a proprietary reference range.